Denosumab biosimilar (Accord Healthcare)

地舒单抗生物类似药 (Accord Healthcare)

Report date: 2025/12/01 11:08:18

Base Information

Drug NameDenosumab biosimilar (Accord Healthcare)
Drug Alias NameOsvyrtiJubereq
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesHypercalcemiaBone Resorption +[7] 
Global Approved IndicationsHypercalcemiaBone ResorptionOsteoporosis, Postmenopausal +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/05/26
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAccord Healthcare Slu
China Registration ClassN/A

Develop Information

Active CompaniesAccord Healthcare LtdAccord Healthcare SluAccord Biopharma Inc
Inactive CompaniesN/A
Active IndicationsBone metastasesHypercalcemiaBone Resorption +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A